/

VCEL

Vericel CorporationPre-market

40.62+0.52 +1.30%USD

NasdaqGM · as of Oct 12, 16:00 ET · 15m delay

Open

39.00

Prev close

40.10

Day range

39.0040.70

52-week range

28.9549.32

Volume

432.88K0.85×

Mkt cap

2.08B

P/E ttm

86.43

Fwd P/E

48.01

EPS ttm

0.4700

Div yield

0.00%

Earnings

Jul 30, 2026

From 52w high

−17.64%

Price Chart

Yahoo Finance · delayed

VCELOct 12, 2026O 40.30H 40.81L 39.00C 40.62+0.52 (+1.30%)Vol 432.90K

SMA 5041.45
SMA 20038.39

1Y change +27.54% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

VCEL Vericel Corporation · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.10%
1 month: +5.95%
3 months: −14.47%
6 months: +17.94%
Year to date: +12.80%
1 year: +27.54%

Valuation & ownership

Market cap: 2.08B
Enterprise value: 2.01B
P/E (ttm): 86.43
Forward P/E: 48.01
PEG ratio: —
Price / book: 5.62
Price / sales (ttm): 6.79
EV / EBITDA: 64.54
EPS (ttm): 0.4700
EPS (forward): 0.8460
Beta (5y monthly): 1.02
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 51.21M
Float: 50.58M
Short % of float: 13.09%
Short ratio (days): 10.21
Held by insiders: 1.19%
Held by institutions: 110.43%
Avg volume (3m): 508.41K
50-day average: 41.45
200-day average: 38.39
52-week change: +27.54%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 51.2
vs 50-day SMA: −1.99%
vs 200-day SMA: +5.80%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.38%
Realised vol (20d, ann.): 26.0%
From 52-week high: −17.64%
From 52-week low: +40.31%

ANR

Analyst Consensus

7 analysts

Consensus

Strong buy

1.25 on a 1 (strong buy) – 5 (sell) scale

Mean target

60.57

+49.12% implied

Low 55.00Median 59.00High 72.00

Recommendation trend

Now7 / 1 / 0
1m ago7 / 1 / 0

DES

About Vericel Corporation

Yahoo Finance profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Sector: Healthcare
Industry: Biotechnology
Employees: 398
Headquarters: Burlington, MA, United States
Website: vcel.com
Officers: Mr. Dominick C. Colangelo Esq. CEO, President & Director
Mr. Joseph Anthony Mara Jr. CFO & Treasurer
Mr. Michael Halpin Chief Operating Officer

SEAS

Seasonality · VCEL

2007–2026 · monthly returns

Strongest month Mar +8.79%Weakest month Aug −2.51%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-0.1	-0.8	-9.8	8.0	-4.0	33.5	3.3	-13.2	0.6	1.2			+12.8%
2025	6.6	-12.4	-13.0	-14.8	8.6	3.0	-17.9	4.1	-13.4	11.4	14.8	-10.5	−34.4%
2024	20.7	6.3	13.9	-11.8	4.0	-3.8	10.1	2.2	-18.2	4.2	32.0	-5.6	+54.2%
2023	4.3	10.7	-3.6	7.5	1.9	17.0	-4.4	-8.6	2.1	5.0	1.0	0.2	+35.2%
2022	-9.5	15.8	-7.3	-25.4	-4.7	-7.3	29.2	-23.3	-7.0	15.9	-15.1	15.4	−33.0%
2021	33.6	17.0	15.1	12.4	-9.5	-7.1	0.8	2.3	-9.9	-5.7	-19.1	5.6	+27.3%
2020	-5.7	-5.9	-40.6	58.1	-0.8	-3.9	19.3	-3.9	16.9	0.0	37.8	20.9	+77.5%
2019	-1.1	8.8	-6.4	-3.0	-7.9	20.7	1.2	-13.5	-8.5	4.8	17.6	-6.8	+0.0%
2018	41.3	3.9	24.4	34.2	0.7	-27.9	7.7	16.7	16.0	-21.2	57.7	-1.0	+219.3%
2017	-13.3	15.4	-6.7	-7.1	13.5	11.9	-1.5	32.3	39.5	-24.2	-2.2	22.5	+81.7%
2016	-18.2	-4.3	190.1	-50.9	-2.8	-19.6	0.4	-0.9	25.0	-21.4	9.1	25.0	+16.3%
2015	3.6	14.3	2.8	-10.5	-6.0	14.8	-5.0	-7.4	-13.7	-22.1	11.4	9.8	−15.1%
2014	11.8	-6.6	30.3	-9.8	27.5	-18.8	-22.9	22.5	-26.4	3.9	-5.4	8.6	−5.9%
2013	6.3	-9.0	-42.6	-14.3	-5.0	-29.8	2.5	-34.1	3.7	-28.6	8.7	-25.7	−87.2%
2012	8.2	-9.1	12.8	26.7	-22.3	8.0	-9.8	-13.9	-2.4	-11.7	-10.4	-2.3	−30.8%
2011	3.9	-18.4	15.2	8.4	20.7	-15.9	-8.4	2.8	-13.5	14.3	-17.2	-14.2	−28.9%
2010	-32.3	-7.7	6.5	-1.8	-8.6	0.7	6.0	-5.7	4.0	31.0	18.7	6.2	+3.2%
2009	46.0	-49.3	2.7	0.0	-10.5	23.5	-4.8	2.5	4.9	-27.9	-16.1	19.2	−38.0%
2008	15.4	-13.3	-23.1	0.0	-2.5	-5.1	0.0	-13.5	-21.9	60.0	-7.5	35.1	−3.8%
2007	7.3	8.3	-3.5	3.6	-2.1	-4.3	-9.7	-8.3	4.5	-11.2	-10.7	-43.5	−57.7%

INSD

Insider Activity · VCEL

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

104.6K shares

Sells, 6 months

110.5K shares

Net shares

−5.9K

Net change in insider shares

−1.00%

Date	Insider	Transaction	Shares	Value
Aug 11, 2026	Mclaughlin Kevin FDirector	Sale at price 44.53 per share.	7K	$311.71K
Aug 11, 2026	Mclaughlin Kevin FDirector	Conversion of Exercise of derivative security at price 13.05 per share.	7K	$91.35K
Aug 2, 2026	Halpin MichaelChief Operating Officer	Sale at price 46.84 per share.	10K	$468.40K
Aug 2, 2026	Halpin MichaelChief Operating Officer	Conversion of Exercise of derivative security at price 16.66 per share.	10K	$166.60K
Jul 29, 2026	Siegal Jonathan D.Officer	Sale at price 48.90 per share.	4.5K	$220.05K
Jul 29, 2026	Siegal Jonathan D.Officer	Conversion of Exercise of derivative security at price 29.82 - 34.90 per share.	4.5K	$141.81K
Jun 25, 2026	Hopper Jonathan MarkOfficer	Sale at price 45.00 per share.	10K	$450.00K
Jun 25, 2026	Hopper Jonathan MarkOfficer	Conversion of Exercise of derivative security at price 29.82 per share.	10K	$298.20K
Jun 25, 2026	Flynn Sean COfficer	Sale at price 45.64 per share.	15K	$684.60K
Jun 25, 2026	Flynn Sean COfficer	Conversion of Exercise of derivative security at price 16.25 per share.	15K	$243.75K
Jun 25, 2026	Mara Joseph Anthony JrChief Financial Officer	Sale at price 44.75 per share.	5K	$223.75K
Jun 25, 2026	Siegal Jonathan D.Officer	Sale at price 44.90 per share.	2.7K	$122.67K
Jun 25, 2026	Siegal Jonathan D.Officer	Conversion of Exercise of derivative security at price 29.82 per share.	2.5K	$74.55K
Jun 17, 2026	Halpin MichaelChief Operating Officer	Sale at price 40.24 per share.	10K	$402.40K
Jun 17, 2026	Halpin MichaelChief Operating Officer	Conversion of Exercise of derivative security at price 16.66 per share.	10K	$166.60K
Jun 17, 2026	Flynn Sean COfficer	Sale at price 40.21 per share.	15K	$603.15K
Jun 17, 2026	Flynn Sean COfficer	Conversion of Exercise of derivative security at price 16.25 per share.	15K	$243.75K
Jun 1, 2026	Hopper Jonathan MarkOfficer	Sale at price 35.00 per share.	4.4K	$153.13K
Jun 1, 2026	Hopper Jonathan MarkOfficer	Conversion of Exercise of derivative security at price 16.66 per share.	4.4K	$72.89K
May 12, 2026	Mclaughlin Kevin FDirector	Sale at price 32.82 - 32.83 per share.	7K	$229.78K

VCEL

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

VCEL

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vericel Corporation

Seasonality · VCEL

Insider Activity · VCEL

Congress Trades · VCEL

Investors Holding VCEL

Investors Holding VCEL

Congress Trades · VCEL

Insider Activity · VCEL

Seasonality · VCEL

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Vericel Corporation

Financial Snapshot

Earnings & Dividends

News